查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1735693

全球腦炎疫苗市場規模（按菌株、最終用戶、區域覆蓋範圍和預測）

Global Encephalitis Vaccine Market Size By Strain (Nakayama, Beijing, P-3, SA 14-14-2), By End User (Child, Adult), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

腦炎疫苗市場規模及預測

2024 年腦炎疫苗市場規模為 12.6913 億美元，預計到 2032 年將達到 18.7565 億美元，2026 年至 2032 年的複合年成長率為 5.52%。

腦炎病毒感染導致的高死亡率和發病率令人擔憂，這正在提高多個地區的認知度，並推動市場成長。各種政府措施、明確的政策和充足的治療補貼正在促進市場的成長。 《全球腦炎疫苗市場報告》對市場進行了全面評估，全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及影響市場的關鍵因素。

定義全球腦炎疫苗市場

腦炎病毒是一種蚊媒黃病毒，由蚊子傳播給候鳥、豬和其他脊椎動物宿主。該病毒可以透過腦炎疫苗來預防。腦炎病毒的發生率通常較低，但因地區和季節而異。腦炎疫苗可以預防該病毒。腦炎病毒可透過受感染蚊子的叮咬在人與人之間傳播，在農村農業地區最為常見，其中亞太地區的病例最多。

全球腦炎疫苗市場概況

由於腦炎病毒造成的高死亡率，全球市場正以相對較高的成長率擴張。政府不斷加強對兒童接種疫苗的鼓勵，也推動了市場的成長。關於這些疫苗益處的宣傳活動和項目的增多，也為市場帶來了機會。綜合來看，這些因素預計將在不久的將來增加對腦炎疫苗的需求。

目錄

第1章全球腦炎疫苗市場介紹

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球腦炎疫苗市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球腦炎疫苗市場（按菌株）

  • 概述
  • 中山
  • 北京
  • P-3
  • SA1414-2

6. 全球腦炎疫苗市場（依最終用戶）

  • 概述
  • 孩子們
  • 成人

7. 全球腦炎疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東和非洲

8. 全球腦炎疫苗市場競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第9章 公司簡介

  • Liaoning Chengda
  • Valneva
  • Tiantan Biological Products
  • Sanofi Pasteur
  • Chengdu Institute of Biological Products
  • GlaxoSmithKline plc
  • Lanzhou Institute of Biological Products
  • Zhejiang Tianyuan Bio-Pharmaceutical
  • Biken

第10章 附錄

  • 相關調查
簡介目錄
Product Code: 35644

Encephalitis Vaccine Market Size And Forecast

Encephalitis Vaccine Market size was valued at USD 1269.13 Million in 2024 and is projected to reach USD 1875.65 Million by 2032, growing at a CAGR of 5.52% from 2026-2032.

The high mortality and morbidity rate caused due to the incidence of encephalitis virus is an alarming factor that is creating awareness among multiple regions and is driving the market growth. The inititives by various government and easy policies and proper treatment aids are contributing to the growth of the market. The Global Encephalitis Vaccine Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Encephalitis Vaccine Market Definition

Encephalitis virus is a mosquito-borne Flavivirus that can be transmitted from mosquitoes to wading birds, pigs and other vertebrate hosts. This virus can be prevented using Encephalitis vaccines. The incidence rate for the Encephalitis virus is in a general low but can depend on the location and the season. This virus can be prevented using Encephalitis vaccines. As an Encephalitis infected mosquito bite can also be transmitted through humans and most commonly occurs in rural agricultural areas, thus Asia Pacific has witnessed the most number of cases.

Global Encephalitis Vaccine Market Overview

The global market is witnessing expansion at a relatively higher growth rate owing to the high mortality rate caused due to the encephalitis virus. The rise in government initiatives and recommendations to immunize children is also aiding the growth of the market. Factors such as the growing number of campaigns and programs for the improvement in awareness regarding the benefits of these vaccines are acting as an opportunity for the market. These factors, collectively, are projected to increase the demand for Encephalitis Vaccine in the near future.

Global Encephalitis Vaccine Market Segmentation Analysis

The Global Encephalitis Vaccine Market is segmented on the basis of Strain, End-User, And Geography.

Encephalitis Vaccine Market, By Strain

  • Nakayama
  • Beijing
  • P-3
  • SA 14-14-2

Based on Strain, The market is bifurcated into Nakayama, Beijing, P-3, SA 14-14-2. The Nakayama segment accounts for the largest share in the encephalitis vaccine market by strain. It is followed by beijing.

Encephalitis Vaccine Market, By End-User

  • Child
  • Adult

Based on End-User, The market is bifurcated into Child and Adult. The Encephalitis is seen in children and the adult population. Comparitively, Adult section regisets more number of individuals that are affected each year.

Encephalitis Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Regional Analysis, The Global Encephalitis Vaccine Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America is anticipated to dominate the Encephalitis Vaccine Market and account for the largest share during the forecast period. Rise in investment from the government and public sector and programs to eradicate the disease from the region are the few factors expanding the growth of the market in the North American region. However, the Asia-Pacific market is anticipated to be the fastest-growing market during the forecast period. The prevalence of government-induced immunization programs, growing investment in R&D sector and entry of new vaccine manufacturers in the countries like India and China are majorly possible for the growth of the region.

Key Players

The "Global Encephalitis Vaccine Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Liaoning Chengda, Valneva, Tiantan Biological Products, Sanofi Pasteur, Chengdu Institute of Biological Products, GlaxoSmithKline plc, Lanzhou Institute of Biological Products, Zhejiang Tianyuan Bio-Pharmaceutical, and Biken. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • Partnerships, Collaborations and Agreements
  • April, 2020 Pfizer Inc. and Valneva SE ("Valneva") announced a collaboration to develop and commercialise Valneva's Lyme disease vaccine candidate VLA15, which is currently in Phase 2 clinical trials.
  • July 2021. GSK and Alector announce a global immuno-neurology collaboration for two clinical-stage first-in-class monoclonal antibodies for neurodegenerative diseases.
  • June 23, 2020. Sanofi and Translate Bio are expanding their collaboration to develop mRNA vaccines for all infectious diseases.
  • Mergers and Acquisitions
  • September 2020 - Sanofi announced that its acquisition of Principia Biopharma Inc. ("Principia") for $100 per share in cash has been completed.
  • April 2020. Over a year after the Rs31,700 crore mega-deal was first announced, Hindustan Unilever Ltd (HUL) has completed the merger of GlaxoSmithKline Consumer Healthcare Limited (GSKCH) with itself. HUL will distribute GSK brands such as Eno, Crocin, and Sensodyne in the country under the terms of the agreement.
  • Product Launches and Product Expansions
  • March 31, 2021. Sanofi will construct a new facility in Canada to increase the global availability of high-dose influenza vaccine.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ENCEPHALITIS VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ENCEPHALITIS VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ENCEPHALITIS VACCINE MARKET, BY STRAIN

  • 5.1 Overview
  • 5.2 Nakayama
  • 5.3 Beijing
  • 5.4 P-3
  • 5.5 SA1414-2

6 GLOBAL ENCEPHALITIS VACCINE MARKET, BY END USER

  • 6.1 Overview
  • 6.2 Child
  • 6.3 Adult

7 GLOBAL ENCEPHALITIS VACCINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East & Africa

8 GLOBAL ENCEPHALITIS VACCINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Liaoning Chengda
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Valneva
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Tiantan Biological Products
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Sanofi Pasteur
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Chengdu Institute of Biological Products
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 GlaxoSmithKline plc
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Lanzhou Institute of Biological Products
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Zhejiang Tianyuan Bio-Pharmaceutical
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Biken
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments

10 Appendix

  • 10.1 Related Research